Navigation Links
Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl® and Agreement of the Phase 3 Program
Date:2/17/2012

ASHBURN, Va., Feb. 17, 2012 /PRNewswire/ -- Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl® and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl® is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair. FDA agreed to the Phase 3 clinical studies that Innocoll proposed and confirmed that, if successful, those studies should be sufficient to support a future NDA submission.   

Commenting on the announcement, Dr. Michael Myers, Innocoll's President and CEO said, "We are pleased to announce yet another significant milestone for Innocoll.  With the recent EU approval of  CollaGUARD® Adhesion Barrier and with Cogenzia®, for diabetic foot infections, also ready to start Phase 3, Innocoll's portfolio of late stage assets is stronger than ever."  

About XaraColl®

XaraColl® is a biodegradable and fully resorbable collagen/bupivacaine matrix formulated and manufactured using Innocoll's proprietary collagen-based drug delivery technology, CollaRx®. This technology achieves a high concentration of drug at the target tissue, while maintaining low systemic levels.  XaraColl® is intended to provide pain control directly at the surgical site and thus reduce the level of additional analgesia required following surgery.  The product is available in several different strengths, and is designed such that multiple units can be used per patient, for optimum dosing flexibility and efficacy.  XaraColl® is easy to use and can be cut or rolled depending on the surgical setting and can be used laparoscopically. 

About Innocoll, Inc.

Innocoll is a privately
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Innocoll Announces Appointment of Anthony H. Wild Ph.D. to Chairman of the Board
2. Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
3. Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge
4. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
5. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
6. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
7. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
8. Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
9. Auxilium Announces Appointments to Enhance Leadership Team
10. Spherix Announces Registered Direct Offering of $1.15 Million
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... 23, 2014 Nashville Fertility Center announced ... treasurer for the American Society for Reproductive Medicine (ASRM), ... research in reproductive medicine. In his new role ... the executive board and will have a voice in ... has actively supported ASRM since 1984 when he joined ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... Dissolve Powder Antacid Delivers Faster Relief, ... Increased Convenience and Great Taste, PITTSBURGH, April ... integrated marketing campaign,for the new TUMS(R) QuikPak(TM), the first and ... QuikPak campaign, part of,a larger new "Bring It On" brand ...
... - MIGENIX Inc.,(TSX: MGI, OTC: MGIFF), a clinical-stage ... Dorsman to its Board of Directors. Mr.,Dorsman is ... a,financial consulting firm in Vancouver, which advises companies ... overall business,strategies. Prior to founding his consulting firm ...
... Sirion Therapeutics, Inc., a,privately held ophthalmic-focused biopharmaceutical company, ... targeted for the,treatment of retinal diseases will be ... for Research in Vision and Ophthalmology (ARVO),April 27 ... http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO ), "We are very ...
Cached Biology Technology:New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons 2MIGENIX Appoints Pieter Dorsman to Board of Directors 2Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO 2Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO 3
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... Researchers at the University of Alabama at Birmingham (UAB) ... grow and remodel themselves to stay strong, a finding ... osteoporosis drugs, the researchers said The coupling factor ... or TGF beta-1. Previously, scientists had searched for but ...
... "Push your finger as hard as you can against the ... slowly - follow the ticking clock. Now faster. Now faster." ... experiment that casts doubt on old ideas about mechanisms to ... explain why manual dexterity is so vulnerable to aging and ...
... Ore. A 700-mile security wall under construction along ... the movement and "connectivity" of wildlife, biologists say, and ... of some species. However, technology and alterations to ... to move more freely between the two countries, the ...
Cached Biology News:UAB study reveals bone coupling factor key to skeletal health 21-finger exercise reveals unexpected limits to dexterity 21-finger exercise reveals unexpected limits to dexterity 3US-Mexico border wall could threaten wildlife species 2US-Mexico border wall could threaten wildlife species 3US-Mexico border wall could threaten wildlife species 4
... system is used for single-color real-time detection ... or JOE fluorophores and features a real-time ... data from 96 wells, a gene expression ... analysis. The system includes the optical module ...
... PCR detection system offers an affordable alternative ... dyes such as FAM and SYBR Green ... iCycler thermal cycler, offering superior features such ... The MyiQ real-time PCR detection system is ...
... systems are highly sensitive laser confocal systems ... are advanced scanners that meet your expectations, ... level, and optimizing the signal on the ... of the range for increased sensitivity. Results ...
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
Biology Products: